AMGEN®

Prolia [®] Safety Data Sheet

Date Issued 01-Feb-2013

1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY/UNDERSTANDING

1.1 Product identifier

Product Name:

Common Name:

Chemical Name:

Synonyms:

Prolia

Denosumab

Not Applicable

AMG 162, desnoumab

1.2 Relevant identified uses of the substance or mixture and uses advised against

Recommended Use: Pharmaceutical
Uses advised against: No information available

Manufacturer: Emergency Telephone Number:

Amgen Inc. Chemtrec

One Amgen Center Drive NORTH AMERICA 1-800-424-9300, Thousand Oaks, California 91320-1799 INTERNATIONAL 1-703-527-3887

1-805-447-7233 1-805-447-1000

2. HAZARDS IDENTIFICATION

Emergency Overview

Pharmaceutical product intended for clinical and manufacturing purposes only. Product contains denosumab, an active pharmaceutical ingredient for the treatment of bone diseases characterized by excessive bone resorption, including those from cancer-related bone destruction; treatment-related bone loss; and pathologic bone loss. The pharmacologic action of Prolia® appears to be reversible. Avoid inhalation, skin contact, eye contact, and accidental ingestion. Does not meet GHS classification criteria and therefore is not classified.

2.1 - Classification of the drug substance or mixture (drug product in final form, not applicable) REGULATION (EC) No 1272/2008

Not classified

Classification according to EU Directives 67/548/EEC or 1999/45/EC

For the full text of the R phrases mentioned in this Section, see Section 16

2.2 Label elements

Not classified

2.3 Other Hazards No information available

AMGEN® Revision Number: 6

Prolia ® Safety Data Sheet

Date Issued 01-Feb-2013

3. COMPOSITION/INFORMATION ON INGREDIENTS

3.1 Substances

Ingredients: Proprietary information

Chemical Name: Not Applicable

CAS-No: 615258-40-7

Each 1 mL single-use vial of Prolia® contains 60 mg denosumab (60mg/mL solution) and the following:

	CAS Number:	Amount
Sorbitol	50-70-4	4.7 %
Sodium acetate	127-09-3	17 mM
Water for Injection, USP	7732-18-5	

Each 1 mL single-use prefilled syringe of Prolia® contains 60 mg denosumab (60mg/mL solution) and the following:

	CAS Number:	Amount
Sorbitol	50-70-4	4.7 %
Sodium acetate	127-09-3	17 mM
Water for Injection, USP	7732-18-5	

4. FIRST AID MEASURES

4.1 Description of first-aid measures

Eye Contact: In the case of contact with eyes, rinse immediately with plenty of water and seek medical

advice.

Skin Contact: Wash off immediately with soap and plenty of water removing all contaminated clothes and

shoes. Consult a physician if necessary.

Inhalation: Move to fresh air. If symptoms persist, call a physician.

Ingestion: If symptoms persist, call a physician. Do not induce vomiting without medical advice. Never

give anything by mouth to an unconscious person.

Notes to Physician: Treat symptomatically.



Prolia ® Safety Data Sheet

Date Issued 01-Feb-2013

5. FIRE-FIGHTING MEASURES

5.1 Extinguishing media

Flammable Properties: Not applicable/aqueous solution.

Extinguishing Media: Use extinguishing measures that are appropriate to local circumstances and the

surrounding environment.

5.2 Special hazards arising from the substance or mixture

Hazardous Combustion Products: None

5.3 Advice for firefighters

Protective Equipment and Precautions for Firefighters:

Spill Procedures:

As in any fire, wear self-contained breathing apparatus pressure-demand, NIOSH

(approved) and full protective gear.

6. ACCIDENTAL RELEASE MEASURES

6.1 Personal precautions, protective equipment and emergency procedures

If material is released or spilled, cordon off spill area. Take proper precautions to minimize exposure by using appropriate personal protective equipment in cleaning up a spill. If in powder form, wet down spilled material to minimize airborne dispersion. Soak up material with absorbent e.g., paper towels, and wash spill area thoroughly with appropriate cleaning materials. Dispose of collected material in accordance with applicable waste disposal

regulations. Avoid release to the environment.

7. HANDLING AND STORAGE

7.1 Precautions for Safe Handling

Handling and Storage: Avoid contact with skin, eyes or clothing. Do not eat, drink or smoke in work areas. Use

adequate ventilation to minimize exposure. Wash hands, face and other potentially exposed areas immediately after handling this material. Remove contaminated clothing prior to entering eating areas. Clean protective equipment thoroughly after each use. Store

in a well ventilated area.



Prolia [®] Safety Data Sheet

Date Issued 01-Feb-2013

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

8.1 Control parameters

Occupational Exposure Limit: No exposure guidelines established by ACGIH, NIOSH or OSHA. Amgen recommends an

occupational exposure limit (OEL) of $60 \, \mu g/m^3$ as an 8-hour time weighted average over a 40-hour work week. The OEL is designed as an acceptable airborne concentration of a substance for which it is believed that workers may be repeatedly exposed day after day without adverse health effects. Prolia® has been classified per Amgen's Hazard

Classification System as an Occupational Exposure Band 3 compound (20 $\mu g/m^3$ - 100

 μ g/m³).

Engineering Controls: When practicable, handle material in enclosed processes or in processes with effective

local exhaust ventilation or within a chemical hood.

8.2 Exposure controls

Personal Protective Equipment

Eye/face Protection: Wear safety glasses with side shields, chemical splash goggles, or safety glasses with side

shields and a full-face shield to prevent contact with eyes. The choice of protection should

be based on the job activity and potential for exposure to the eyes and face.

Skin Protection: Use gloves or other appropriate personal protective equipment if skin contact with

formulation is possible. Wear lab coat or other protective over garment if splashing is possible. The choice of protection should be based on the job activity and potential for skin

contact.

Respiratory Protection: When possible, handle material in enclosed processes or containers. If it is properly

handled with effective local exhaust ventilation or containment, respiratory protection may not be needed. For procedures involving larger quantities or dust/aerosol generating procedures such as weighing or a large transfer of liquids, an air-purifying respirator with

NIOSH approval for dusts and mists may be needed.

Other: Wash hands, face and other potentially exposed areas after handling material (especially

before eating, drinking or smoking). Clean protective equipment thoroughly after each use.

8.3 Environmental exposure controls

Environmental Exposure Controls Avoid release to the environment.



Prolia [®] Safety Data Sheet

Date Issued 01-Feb-2013

9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance: Clear colorless to slightly yellow

Physical State: Liquid Molecular Weight: 147kD

Odor: No information available Odor Threshold: No information available

pH: 5.2

Melting Point:Not applicableFlash Point:Not applicable

Evaporation Rate:

Lower explosive limit:

Upper explosive limit:

Vapor Pressure:

Vapor Density (air = 1):

Relative density:

No information available
No information available
No information available
No information available

Water Solubility: Not applicable

Partition Coefficient (log Kow): No information available No information available

10. STABILITY AND REACTIVITY

10.1 Reactivity No information available

10.2 Chemical stability Stable

reactions

10.3 Possibility of hazardous No information available

10.4 Conditions to avoidNo Information available

10.5 Incompatible materials No information available

10.6 Hazardous

decomposition products

No information available

10.7 Other information None



Prolia ® Safety Data Sheet

Date Issued 01-Feb-2013

11. TOXICOLOGICAL INFORMATION

11.1 Information on toxicological effects

Acute Toxicity:

Skin corrosion/irritation:

Serious eye damage/eye irritation:

Respiratory or skin sensitization:

Germ cell mutagenicity:

Carcinogenicity:

No information available
No information available
No information available
No information available

Reproductive toxicity: Even though this does not meet GHS classification, the following data is available: Prolia®

exposure in cynomolgus monkeys by subcutaneous injection at 50 mg/kg from gestation day 20 to parturition resulted in increased fetal loss, stillbirths, and postnatal mortality, along with histological changes in infants. In general, the effects observed in mothers and infants were consistent with the pharmacological action of denosumab as a monoclonal antibody against RANKL and an inhibitor of osteoclastic bone resorption. No effects on

male or female fertility have been observed.

STOT - single exposure: No information available

STOT - repeated exposure: Even though this does not meet GHS classification, the following data is available: Prolia®

was administered to cynomolgus monkeys via subcutaneous injection once monthly for 1 year at doses of 1, 10 and 50 mg/kg and no adverse effects were observed. Denosumab produced rapid and sustained decreases in markers of bone turnover and increases in bone mineral density at doses >1 mg/kg, which were attributable to the pharmacologic

activity of the monoclonal antibody.

Aspiration Hazard: No information available



Prolia ® Safety Data Sheet

Date Issued 01-Feb-2013

12. ECOLOGICAL INFORMATION

12.1 Toxicity

Ecotoxicity effects: No information available

12.2 Persistence and degradability

Persistence/Degradability: No information available

12.3 Bioaccumulative potential

Bioaccumulation/ Accumulation: No information available

12.4 Mobility in soil

Mobility in Environmental Media: No information available

12.5 Results of PBT and vPvB assessment

Results of PBT and vPvB assessment: No information available

12.6 Other adverse effects

Other Adverse Effects: No information available

13. DISPOSAL CONSIDERATIONS

13.1 Waste treatment methods

Waste Disposal Method: Dispose of any waste according to prescribed federal, state, local and competent authority

guidelines.

14. TRANSPORT INFORMATION

DOT Not regulated by U.S. DOT or IATA



Prolia ® Safety Data Sheet

Date Issued 01-Feb-2013

15. REGULATORY INFORMATION

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

International Inventories

TSCA:
EINECS/ELINCS
DSL/NDSL
PICCS:
ENCS:
CHINA:
AICS:
KECL:

Legend

TSCA - United States Toxic Substances Control Act Section 8(b) Inventory

EINECS/ELINCS - European Inventory of Existing Commercial Chemical Substances/EU List of Notified Chemical Substances

DSL/NDSL - Canadian Domestic Substances List/Non-Domestic Substances List

PICCS - Philippines Inventory of Chemicals and Chemical Substances

ENCS - Japan Existing and New Chemical Substances

IECSC - China Inventory of Existing Chemical Substances

AICS - Australian Inventory of Chemical Substances

KECL - Korean Existing and Evaluated Chemical Substances

State Regulations

California Proposition 65: This product does not contain any Proposition 65 chemicals.

15.2 Chemical safety assessment

No CSA has been conducted.



Prolia ® Safety Data Sheet

Date Issued 01-Feb-2013

16. OTHER INFORMATION

Text of R phrases mentioned in Section 2

No information available

Revision Number: 6

The above information is based on data available to us and is believed to be correct. Since the information may be applied under conditions beyond our control and with which we may be unfamiliar, we do not assume any responsibility for the results of its use and all persons receiving it must make their own determination of the effects, properties and protections, which pertain to their particular conditions.

No representation, warranty, or guarantee, express or implied (including a warranty of fitness or merchantability for a particular purpose), is made with respect to the materials, the accuracy of this information, the results to be obtained from the use thereof, or the hazards connected with the use of the material. Caution should be used in the handling and use of the material because it may be biologically active.